Neurological Manifestations in Children Diagnosed With Inflammatory Bowel Disease
NCT07247994
Colonic Diseases, Colonic Diseases, Functional
View Trial DetailsNCT Number: NCT06638814
Patients who will undergo surgery for HD after the diagnosis of IBD over a 12-month period will be enrolled across Europe.
Primary objective of this study is to determine the safety and effectiveness of surgical treatments for HD in a large multicenter cohort of IBD patients.
Secondary aim is to identify factors that may affect clinical and surgical outcomes.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
To date, there is no consensus in the scientific literature regarding the exact indications for surgery for hemorrhoidal disease (HD) in patients with inflammatory bowel disease (IBD). The HEAD-IBD-II study is a multicenter, prospective cohort designed to evaluate the safety and effectiveness of surgical treatments for hemorrhoidal disease (HD) in patients with inflammatory bowel disease (IBD). This study aims to collect contemporary, real-world data from multiple hospitals across various countries, focusing on the surgical management of HD in this unique patient population. The study will include adult patients with a confirmed diagnosis of Crohn's disease or ulcerative colitis who undergo surgery for HD.
The data collection process will involve detailed records of patient demographics, pre-operative status, operative techniques, and post-operative outcomes, with a specific focus on short-, medium-, and long-term surgical and clinical results. The study will track outcomes such as postoperative complications, recurrence of symptoms, IBD flare-ups, and anal continence.
In addition, factors such as surgical volume, techniques employed, and individual patient characteristics will be analyzed to identify variables that may impact the outcomes. The study is designed to generate hypotheses and explore variability in current practices, thereby highlighting areas in need of further investigation through randomized controlled trials.
All patient data will be collected anonymously through a secure electronic case report form (eCRF), and results will be disseminated according to the STROBE guidelines for observational studies. Ethical approval will be obtained from participating institutions, and all patients will provide informed consent prior to inclusion. The study is expected to improve the understanding of surgical approaches to HD in IBD patients and potentially guide future clinical recommendations.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 12 months from surgery
Data on patient demographics and clinical characteristics, operative details, and clinical and surgical outcomes will be collected.
The surgical outcomes will include: length of hospital stay, 30-day readmission, and post-operative complications at medium- (6 months) and long-term (12 months) follow-up.
The clinical outcomes will include: IBD flare, defined according to standard scores (i.e., partial Mayo score for ulcerative colitis and Harvey-Bradshaw Index for Crohn's disease) and need for therapeutic change or dose escalation during the 6 months after surgery, new onset of perianal disease, anal continence status at last follow-up.
Contact information is provided by the study sponsor or research team.
Chiara Carniel
CONTACT
Ugo Grossi, MD PhD
CONTACT
Treviso Regional Hospital
Network
Acronym: HEAD-IBD-II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07247994
Colonic Diseases, Colonic Diseases, Functional
View Trial DetailsNCT07240181
Colitis, Colitis Ulcerative
Hvidovre, Denmark
View Trial DetailsNCT07205549
Digestive System Diseases, Gastroenteritis
View Trial DetailsNCT07177157
Colitis, Colitis, Ulcerative
London, Ontario, Canada
View Trial Details